William C. Stallings, Ph.D.

Dr. Stallings has 18 years of industrial experience. Most recently, he was a Senior Fellow at Pfizer St. Louis where he led a Structural Biology group that included protein crystallography, computational chemistry and NMR spectroscopy. He and his group are credited with the structure-based design of compounds in more than 20 projects, including HIV protease (Amprenivir marketed by GlaxoSmithKline), COX2 (Celebrex, marketed by Pfizer) and EPSP synthase (the enzyme targeted in the development of Roundup Ready crops). Before joining the industrial sector, Dr. Stallings was a Research Scientist at the University of Michigan where he worked on the structures and reaction mechanism of superoxide dismutases. He received a B.S. in chemistry from Washington College, a Ph.D. in Chemistry from the University of Pennsylvania, and he was an NIH Postdoctoral Fellow at the Institute for Cancer Research in Fox Chase. Dr. Stallings is a former chairman of the Industrial Macromolecular Crystallography Association, a pharmaceutical consortium which developed its own beamlines at the Advanced Photon Source. He is a co-editor of Acta Crystallographica, and he served as President of the American Crystallographic Association.